Abstract: Transforming growth factor (TGF)-is a central molecule maintaining the malignant phenotype of glioblastoma. Anti-TGF-strategies are currently being explored in early clinical trials. Yet, there is little contemporary data on the differential expression of TGF-isoforms at the mRNA and protein level or TGF-/Smad pathway activity in glioblastomas in vivo.Here we studied 64 newly diagnosed and 16 recurrent glioblastomas for the expression of TGF-1-3, platelet-derived growth factor (PDGF)-B, and plasminogen activator inhibitor (PAI)-1 mRNA by RT-PCR and for the levels of TGF-1-3 protein, phosphorylated Smad2 (pSmad2), pSmad1/5/8 and PAI-1 by immunohistochemistry.Among the TGFisoforms, TGF-1 mRNA was the most, whereas TGF-3 mRNA was the least abundant. TGF-1-3 mRNA expression was strongly correlated, as was the expression of TGF-1-3 mRNA, and of the TGF-1-3 target genes, PDGF-B and PAI-1. TGF-2 and TGF-3 protein levels correlated well, whereas the comparison of the other TGF-isoforms did not. Positive correlation was also observed between TGF-1 and pSmad1/5/8 and between pSmad2 and pSmad1/5/8. Survival analyses indicated that a group of patients with high expression levels of TGF-2 mRNA or pSmad1/5/8 protein have inferior outcome.We thus provide potential biomarkers for patient stratification in clinical trials of anti-TGF-therapies in glioblastoma. 
Summary
Multisystem deterioration occurs mainly in older individuals and may be related to physiological tissue degeneration. However, genetic predisposition may be unmasked by inappropriate functional and structural system deficiencies. McLeod Syndrome (MLS) is a rare, multisystem disease which is X-chromosomal inherited and belongs to the Neuroacanthocytosis Syndromes (NAS). The main clinical manifestations contain progressive neuro-psychiatric and cognitive deterioration, choreatic movement disorder, as well as myopathy, sensorymotor axonal neuropathy and cardiomyopathy.
In addition, MLS patients have red blood cell abnormalities including immunehematological, morphological and functional impairments of red blood cells. In large deletions, contiguous gene syndrome may arise, including Duchenne muscular dystrophia, cellular immunodeficiency or retinitis pigmentosa. Hematological abnormalities such as blood group abnormalities in Kell-and XK blood group system, formation of anti-public red blood cell alloantibodies, acanthocytosis and elevated creatinine phosphokinase may precede clinical disease manifestation for decades and provide tools for early diagnosis. Patients with unexplained neuro-muscular deterioration and/or neuro-psychological pathologies accompanied with hematological abnormalities should be investigated for MLS.
McLeod Syndrom (MLS) is part of the Neuroacanthocytosis Syndromes (NAS)
NAS are defined as progressive neurodegenerative diseases affecting mainly basal ganglia including nucleus caudatus and putamen in association with red blood cell acanthocytosis. Additional hematological abnormalities e.g. morphological, functional and serological aberrations of red blood cells (RBC) are part of disease defining clinical features. [1] [2] [3] 
Peculiarity of blood group antigens on McLeod erythrocytes
The MLS is the only NAS with distinct blood group abnormality affecting the KEL (ISBT Genetic defects at Xp21.1 lead to the absence or truncation of the XK protein causing both, the reduced or complete absence of the Kell antigen in the erythrocyte membrane, as well as the absence of the Kx blood group antigen (Kx-) 5 . At least 29 different mutations at Xp21.1 are recognized as molecular mechanism for the Kxphenotype 5, 18 . These are missense and stop mutations anywhere in the three exons of the coding sequence as well as splice site and insertion/deletion mutations leading to erroneous translation and transcription of the gene, respectively 5 . In cases of large deletional defects, neighbour genes of XK may also be affected and give rise to the "contiguous gene syndrome" 28 , of which the clinical phenotype is dominated by the co-affected gene(s) 29 . Most important are deletions affecting DMD, a gene located telomeric to XK, leading to Duchenne muscular dystrophy 28 or deletions affecting the centromeric CYBB gene, leading to X-linked granulomatous disease (X-CGD) 30, 31 . Figure 1 gives an overview on some of the molecular defects at Xp21.1 and there consequences for the XK protein. 
Distinct morphology of McLeod erythrocytes

MLS is a multisystem disorder
Although the genetic alteration in MLS was precisely located at Xp21.1 67 the genotype-phenotype correlation is weak and most mutation carriers are discovered while being assessed for a wide spectrum of subtle to severe central nervous system or neuromuscular affection occurring together with pathological changes of red blood cells (acanthocytosis, coombs-negative, hemolytic anemia) [1] [2] [3] 68 . The molecular characterization of underlying genetic defects in NAS allow unambiguous distinction between the four different entities of NAS (Table 1 ). Molecular defect identification has therefore become the key tool for diagnosis 1, 69 . In MLS, the disorder is caused by the affection of the XK protein, which is expressed ubiquitously in body tissues 70 Table 1 ).
Molecular MLS Assessment
As detailed earlier, the NAS are monoallelic deficiency syndromes, perfectly suited for molecular defect analysis. The genetic defects of MLS always involve XK, the gene encoding the XK protein and its Kx antigen, which is located at Xp21. Consequently, this case specific PCR product is then sequenced and allows for the exact definition of the breakpoint position, and may itself already be used as highly accurate diagnostic tool for the detection of a carrier status in mothers, sisters and daughters of affected males. In case, no large X-chromosomal deletion is observed, all three XK exons, also including some sequences of the promoter and at least 50 bp of each flanking intron will be sequenced to reveal point mutations within the gene, potentially causative of an XK inactivating effect. The effect of such point mutations may be clearly evident, e.g. when nonsense mutations lead to the creation of stop codons in the predicted XK peptide, or be less informative and of questionable meaning, e.g. when exchanged amino acids share in between no, and up to similar physiochemical properties, then called "radical" and "conservative missense mutations", respectively. Using this approach we were able to describe five intragenic XK mutants, with only one of them already known and listed as XK*N.20 by the ISBT terminology committee 18 , the others, with as yet undescribed nonsense (n=1), frame shift (n=1) and radical missense mutation (n=1) and two large X-chromosomal deletions, respectively. All carriers had different MLS phenotypes including neuropsychiatric disorder associated with hereditary sudden death syndrome, severe choreatic movement disorder and X-linked CGD, in one case (manuscript in preparation).
Clinically guided MLS diagnosis
Most of the MLS mutations described so far were discovered in patients being investigated for neuro-psychiatric or choreatic movement disorders or in cases with immune deficiency syndromes 5 . Normally, the patients suffer of unspecific neuropsychiatric symptoms for years without having assigned clear diagnosis. Sometimes, MLS is diagnosed in asymptomatic mutation carriers, most often when routinely phenotyped for KEL antigens while serving as blood donors [13] [14] [15] . recognition of orofacial dystonia may be pivotal to prevent feeding impairment and secondary wasting disease 85 . Also, the recognition of private blood type (Kx-) is crucial when it comes to transfusion support. By timely searching for Kx-blood donors from international donor registries or alternatively, by use of cryopreserved autologous blood units the formation of anti-public antibodies can be prevented 23 .
Finally, cardiac complications such as fatal arrhythmia may be prevented by implantation of a cardiac pacemaker 86 .
For genetic counselling of MLS patient's family members, it is important to identify the exact genetic defect which can then be followed for segregation in the relatives of the patient. Finally, in X-linked CGD patients, the exclusion of mutations at Xp21.1 is pivotal in planning and exertion of CGD treatment which often includes stem cell transplantation and transfusion support 87, 88 .
We established an algorithm to comprehensively assess patient's samples for suspected McLeod mutations (Figure 2) 
